Genentech
4 articles
Industry NewsGenentech / AlectorFierce Biotech
Genentech pays Alector $100M upfront for brain-penetrant GCase therapy AL050
- Alector licensed AL050, a preclinical brain-penetrant engineered GCase enzyme replacement therapy for Parkinson's disease, to Genentech.
- The deal brings $100M upfront, up to $1.17B in milestones and tiered royalties; Genentech takes development, manufacturing and commercialization.
- Alector keeps its Brain Carrier platform, and the cash extends its runway into 2029.
A $100M upfront for a preclinical asset shows how much Roche values a validated blood-brain barrier shuttle in GBA1-linked Parkinson's. For Alector, it's a lifeline that funds its Alzheimer's and siRNA programs. The risk is that delivery, not the enzyme, is the real bet, and Genentech has other shuttle options.
Industry NewsBioNTech / GenentechEndpoints News
BioNTech, Genentech Terminate Phase 2 Trial of mRNA Cancer Vaccine Autogene Cevumeran in Colorectal Cancer
- Autogene cevumeran is an individualized, tumor-specific neoantigen mRNA vaccine designed to trigger a T-cell response against a patient's unique tumor mutations.
- Phase 2 trial BNT122-01, run with Genentech, evaluated it as adjuvant monotherapy versus watchful waiting in ctDNA-positive patients with surgically resected Stage II (high-risk) or Stage III colorectal cancer, targeting roughly 327 enrollees with disease-free survival as the primary endpoint.
- BioNTech and Genentech terminated the trial on August 28, 2026, after an independent Data Safety Monitoring Board (DSMB) identified a numerical overall-survival imbalance disfavoring the vaccine arm and concluded continuation was unlikely to change the efficacy outcome; no new safety signals were found.
- A separate, unaffected Phase 2 trial (Imcode003) continues to evaluate autogene cevumeran combined with checkpoint inhibition and chemotherapy in adjuvant pancreatic ductal adenocarcinoma.
- BioNTech shares fell as much as 8% on the news.
An OS imbalance with no new safety signal is a different failure mode than a safety-driven halt — it indicts adjuvant monotherapy in CRC, not necessarily neoantigen mRNA vaccines as a modality. That distinction matters competitively: Moderna/Merck's V940 (INT) has paired its individualized vaccine with pembrolizumab from the outset rather than testing it solo against watchful waiting, and BioNTech's own still-running pancreatic trial (Imcode003) uses that same vaccine-plus-checkpoint-inhibitor-plus-chemo architecture. So the part of the platform that just failed is arguably its least mechanistically ambitious use case. The 8% single-day drop on one Phase 2 readout, though, is the bigger tell — it shows how much of BioNTech's valuation still rests on individualized-vaccine optionality rather than de-risked, validated pipeline.
Industry NewsRoche / GenentechSTAT News
Roche Opens New Innovation Center in Boston Focused on Cardiovascular, Renal and Metabolic Research
- Roche and Genentech held the grand opening of the Roche Genentech Innovation Center Boston, located at Harvard's Enterprise Research Campus in Allston, Massachusetts.
- The 95,000-square-foot facility is leased for 10 years and can accommodate up to 500 employees.
- It will serve as Roche's hub for Cardiovascular, Renal and Metabolic (CVRM) disease research, spanning discovery research, clinical development, and AI/data science.
- The center is designed to provide an end-to-end R&D presence in CVRM, from early discovery through late-stage clinical development.
- The opening forms part of Roche and Genentech's broader $50 billion commitment to U.S. manufacturing and R&D investment, alongside recent expansions in Holly Springs, North Carolina, and Hillsboro, Oregon.
Roche is planting 500 seats squarely in cardiometabolic territory that Novo Nordisk and Eli Lilly currently own by revenue, valuation, and narrative — that's the real story here, not the ribbon-cutting. Roche's own GLP-1/amylin assets (CT-388, petrelintide) are still early and have yet to prove they can compete on efficacy or tolerability — a shiny 95,000-square-foot building doesn't change that math. Read the CVRM bet as portfolio triage as much as ambition: consolidating discovery-through-clinical talent in one hub is what you do when you need faster kill/advance decisions, not just more capacity. And the timing — loud US R&D investment amid tariff and reshoring pressure — reads as much like government-relations optics tied to the $50B pledge as it does science strategy. The signal worth tracking is a phase 2/3 readout from this hub, not the lease signing itself.
Industry NewsGenentech / DualityBioEndpoints News
Genentech Licenses DualityBio's Next-Gen ADC Payload Platform to Counter TOPO1 Resistance
- Genentech has licensed DualityBio's DUPAC antibody-drug-conjugate payload platform: $45M upfront, over $1B in milestones, plus tiered royalties.
- Shanghai-based DualityBio handles target-specific ADC discovery through Phase 1a on Genentech-chosen oncology targets; Genentech then owns exclusive rights through late-stage development and commercialization.
- The rationale is payload resistance — topoisomerase-1 (TOP1) inhibitor payloads underpin most current ADCs, including DualityBio's own BioNTech-partnered HER2 asset, and resistance is rising as these drugs reach earlier treatment lines.
- DUPAC is pitched as a next-gen payload that stays active in TOP1-resistant tumors.
- This follows DualityBio's 2023 BioNTech deal (>$1.5B) and extends MNC pharma's pattern of sourcing ADC payload innovation from China.
The economics: $45M upfront against $1B+ in milestones is a cheap call option for Genentech — DualityBio absorbs discovery and Phase 1a risk, and Genentech only pays once DUPAC clears its resistance hurdle. That's a smaller headline number than DualityBio's 2023 BioNTech deal, hinting at either narrower scope or softer terms on partner #2. Strategically, this is Roche/Genentech hedging against a class-wide ceiling: TOP1 payloads underpin nearly the entire current ADC generation, including Enhertu and DualityBio's own BioNTech HER2 asset, so resistance will bite everyone eventually. It also confirms Genentech won't build payload discovery in-house, joining Pfizer/Seagen and AbbVie/ImmunoGen in sourcing ADC innovation from China. For DualityBio, a second nine-figure MNC partner in three years validates the platform model — though whether DUPAC actually beats resistant tumors is still unproven.